Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Susan Bal(University of Alabama at Birmingham Hospital), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Jaclyn Davis(Bristol-Myers Squibb (United States)), Timothy Pulham(Bristol-Myers Squibb (Sweden)), Ziyan Guo(Bristol-Myers Squibb (Sweden)), Omar Nadeem(Harvard University), Kevin Hsu(Bristol-Myers Squibb (Sweden)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Krishna R. Juluri(Bristol-Myers Squibb (Sweden)), Nizar J. Bahlis(Institute of Cancer Research), Myo Htut(City of Hope), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Krina Patel(The University of Texas MD Anderson Cancer Center), Luciano J. Costa(University of Alabama at Birmingham), Jessica Katz(Memorial Sloan Kettering Cancer Center), Scott R. Solomon(Northside Hospital)
Cited by 0
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497